A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Tiziano Barbui(University of Bergamo), Alessandra Carobbio(Ospedale Papa Giovanni XXIII), Maria Chiara Finazzi(Ospedale Papa Giovanni XXIII), Maria Luisa Ferrari(University of Bergamo), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Silvia Di Tollo(Italfarmaco (Italy)), Giovanni Barosi(Policlinico San Matteo Fondazione), Guido Finazzi(Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"), Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Silvia Salmoiraghi(Ospedale Papa Giovanni XXIII), Carmine D’Urzo(Italfarmaco (Italy)), Elisabetta Gattoni(Policlinico San Matteo Fondazione), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi)
Cited by 242
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k